Planar scintimammography and SPECT in neoadjuvant chemo or hormonotherapy response evaluation in locally advanced primary breast cancer

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1275-1283

  Spanu, Angela ^a   Farris, Antonio ^a   Chessa, Francesca ^a   Sanna, Daniela ^a   Pittalis, Maria ^a   Manca, Alessandra ^a   Madeddu, Giuseppe ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

99mTc tetrofosmin; Dedicated breast camera; Locally advanced primary breast cancer; Neoadjuvant chemotherapy; Neoadjuvant hormonotherapy; Scintimammography; SPECT

Indexed keywords

CISPLATIN; EPIRUBICIN; EXEMESTANE; PACLITAXEL; TETROFOSMIN TC 99M; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAMMOGRAPHY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SCINTIMAMMOGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BREAST TUMOR; COLLOID CARCINOMA; COMPARATIVE STUDY; LUNG CARCINOMA; LYMPH NODE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; LYMPH NODES; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROGNOSIS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 48149112169     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1275     Document Type: Article

References (32)

1. Booser DJ and Hortobagyi GN: Treatment of locally advanced breast cancer. Semin Oncol 19: 278-285, 1992.
2. Semiglazov VF, Semiglazov VV, Dashyan GA, Zitsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A and Berstein LM: Phase 2 randomized trial of primary endocrine therapy vs. chemotherapy in post-menopausal patients with estrogen receptor-positive breast cancer. Cancer 110: 244-254, 2007.
3. Sperber F, Weinstein Y, Sarid D, Ben Yosef R, Shalmon A and Yaal-Hahoshen N: Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer, Isr Med Assoc J 8: 342-346, 2006.
4. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI and Singletary SE: Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243: 257-264, 2006.
5. Maini CL, Tofani A, Sciuto R, Semprebene A, Cavaliere R, Mottolese M, Benevolo M, Ferranti F, Grandinetti ML, Vici P, Lopez M and Botti C: Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med 38: 1546-1551, 1997.
6. Marshall C, Eremin J, El-Sheemy M, Eremin O and Griffiths PA: Monitoring the response of large (>3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using (99m)Tc-Sestamibi uptake. Nucl Med Commun 26: 9-15, 2005.
7. Tiling R, Linke R, Untch M, Richter A, Fieber S, Brinkbaumer K, Tatsch K and Hahn K: 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 28: 711-720, 2001.
8. Spanu A, Dettori G, Nuvoli S, Porcu A, Falchi A, Cottu P, Solinas ME, Scanu AM, Chessa F and Madeddu G: 99mTc-tetrofosmin SPET in both primary breast cancer and axillary lymph node metastasis detection. Eur J Nucl Med 28: 1781-1794, 2001.
9. Spanu A, Schillaci O, Meloni GB, Porcu A, Cottu P, Nuvoli S, Falchi A, Chessa F, Solinas ME and Madeddu G: The usefulness of 99mTc-tetrofosmin SPECT scintimammography in the detection of small size primary breast carcinomas. Int J Oncol 2l: 831-840, 2002.
10. Rhodes DJ, O'Connor MK, Phillips SW, Smith RL and Collins DA: Molecular breast imaging: a new technique using technetiumTc scintimammography to detect small tumors of the breast. Mayo Clin Proc 80: 24-30, 2005.
11. Spanu A, Cottu P, Manca A, Chessa F, Sanna D and Madeddu G: Scintimammography with dedicated breast camera in unifocal and multifocal/multicentric primary breast cancer detection: a comparative study with SPECT. Int J Oncol 31: 369-377, 2007.
12. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds). AJCC Cancer Staging Manual. 6th edition. Springer, New York, 2002.
13. Mouridsen HT, Rose C, Brodie AH and Smith IE: Challanges in the endocrine management of breast cancer. Breast 12 (Suppl 2): S2-S19, 2003.
14. Goss PE: Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol 26: S27-S33, 2003.
15. Freedman OC, Verma S and Clemons MJ: Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31: 1-17, 2005.
16. Schott AF, Roubidoux MA, Helvie MA, Hayes DF, Kleer CG, Newman LA, Pierce LJ, Griffith KA, Murray S, Hunt KA, Paramagul C and Baker LH: Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92: 231-238, 2005.
17. Rodriques M, Chehne F, Kalinowska W, Zielinski C and Sinzinger H: Comparative 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin in human soft tissue sarcoma cell lines. Eur J Nucl Med 27: 1839-1843, 2000.
18. Arbab AS, Koizumi K, Toyama K and Araki T: Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 37: 1551-1556, 1996.
19. Bernard BF, Krenning EP, Breeman WA, Ensing G, Benjamins H, Bakker WH, Visser TJ and De Jong M: 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. Nucl Med Biol 25: 233-240, 1998.
20. Arbab AS, Koizumi K, Toyama K, Arai T and Araki T: Ion transport systems in the uptake of 99Tcm-tetrofosmin, 99Tcm-MIBI and 201 Tl in a tumour cell line. Nucl Med Commun 18: 235-240, 1997.
21. Mekhmandarov S, Sandbank J, Cohen M, Lelcuk S and Lubin E: Technetium-99m-MIBI scintimammography in palpable and non-palpable breast lesions. J Nucl Med 39: 86-91, 1998.
22. Howarth D, Sillar R, Clark D and Lan L: Technetium-99m sestamibi scintimammography: the influence of histopathological characteristics, lesion size and the presence of carcinoma in situ in the detection of breast carcinoma. Eur J Nucl Med 26: 1475-1481, 1999.
23. Khalkhali I, Villanueva-Meyer J, Edell SL, Connolly JL, Schnitt SJ, Baum JK, Houlihan MJ, Jenkins RM and Haber SB: Diagnostic accuracy of 99mTc-Sestamibi breast imaging: multi-center trial results. J Nucl Med 41: 1973-1979, 2000.
24. Scopinaro F, Pani R, De Vincentis G, Soluri A, Pellegrini R and Porfiri LM: High-resolution scintimammography improves the accuracy of technetium-99m methoxyisobutylisonitrile scintimammography: use of a new dedicated gamma camera. Eur J Nucl Med 26: 1279-1288, 1999.
25. Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S and Civelek C: High-resolution scintimammography: a pilot study. J Nucl Med 43: 909-915, 2002.
26. Moskovic EC, Mansi JL, King DM, Murch CR and Smith IE: Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol 47: 339-344, 1993.
27. Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powels TJ, Knee G and Husband JE: Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. Radiology 198: 333-340, 1996.
28. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC and Symmans WF: Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 13: 1443-1449, 2006.
29. Pickles MD, Lowry M, Manton DJ, Gibbs P and Turnbull LW: Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 91: 1-10, 2005.
30. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G and Zuiani C: Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 14: 1371-1379, 2004.
31. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G and Brunereau L: Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30: 1069-1076, 2004.
32. Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B and Burtness BA: Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J 12: 212-221, 2006.